The founders of Zapaq Inc. have a straightforward objective: to develop compounds that inhibit aspartic proteases. The goal is hardly surprising, given that one of the company's founders, Jordan Tang, PhD, of the Oklahoma Medical Research Foundation was the first scientist to determine the structure of an aspartic protease and explore its basic mechanisms.
755 Research Parkway, Suite 427
Oklahoma City, OK 73104
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
